14M Genomics was a cancer diagnostic business that was founded in partnership with the Wellcome Trust Sanger Institute in 2014.
Syncona committed a Series A financing of £12million investing £5.5m to test our investment thesis with milestones for the drawdown of the next tranche of funding that were explicitly designed to test the core investment thesis. The company progressed pre-clinical studies, however, a careful review of the data generated from these studies, did not did not support further investment. We worked collaboratively with the management team to close the business, supporting the team who worked at the company and recovered £0.7m of our investment.
Other previous portfolio portfolio companies
